Overview

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clavis Pharma
Treatments:
Cytarabine